Archive | Clinical Trials

Survival in Advanced Melanoma With Ipilimumab at 10 mg/kg vs 3 mg/kg

In a phase III trial reported by Ascierto et al in The Lancet Oncology, treatment with ipilimumab (Yervoy) at 10 mg/kg vs 3 mg/kg resulted in improved overall survival in patients with advanced unresectable or metastatic melanoma.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Indoximod plus pembrolizumab prompts response in advanced melanoma

The addition of investigational immunotherapy indoximod to pembrolizumab conferred superior response rates in patients with advanced melanoma, according to interim results of a phase 2 clinical trial presented at the American Association for Cancer Research Annual Meeting.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Drug Combo Boosts Response Rate by Half in Melanoma

WASHINGTON — Combining two immune checkpoint inhibitors led to a 50% increase in response rate in advanced melanoma, as compared with the historical rate that led to FDA approval of one of the drugs, investigators reported here.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Opdivo, Yervoy Combo Improved Survival in Advanced Melanoma Phase 3 Trial

Opdivo (nivolumab) in combination with Yervoy (ipilimumab), as well as Opdivo alone, outperformed Yervoy monotherapy in terms of overall survival in a Phase 3 clinical trial of previously untreated patients with advanced melanoma, Bristol-Myers Squibb announced.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories